4D Molecular Therapeutics, Inc. Common Stock (FDMT) Stock
Key stats
- Market cap
- $654.64M
- Price / Earnings ratio
- -3.9x
- EPS (TTM)
- -$2.85
- Volume
- Loading
- 52-week high
- $16.93
- 52-week low
- $6.96
Source: third-party data provider, as of October 24, 2026
Compare with FDMT
Recent news

4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene Therapy
4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene Therapy
FDMT

OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD
OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD
FDMT

OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
FDMT

OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why
FDMT
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 39.04
- MACD 12/26/9
- -0.45
- EMA 9 of MACD
- -0.38
- MACD histogram
- -0.08
- SMA 50
- $14.01
- Price below SMA 50
- EMA 50
- $13.16
- Price below EMA 50
- SMA 200
- $10.75
- Price above SMA 200
- EMA 200
- $11.41
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene Therapy
4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene Therapy
FDMT

OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD
OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD
FDMT

OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
FDMT

OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why
FDMT

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates
FDMT

Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength?
Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength?
FDMT

4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy
FDMT

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
FDMT

4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates
FDMT

6 Underperforming IPO Stocks To Buy On The Dip
6 Underperforming IPO Stocks To Buy On The Dip
FDMT
News tone: automated (AI) classification of the article's content, not a price prediction.
About 4D Molecular Therapeutics, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. David H. Kirn M.D. | Co-Founder, President, CEO & Director | 1962 |
| Dr. John F. Milligan Ph.D. | Executive Chairman | 1961 |
| Mr. Kristian Humer M.B.A. | CFO and Principal Financial & Accounting Officer | 1976 |
| Dr. Fariborz Kamal Ph.D. | Chief Technical Advisor | 1963 |
| Ms. Theresa Janke | Co-Founder & Chief of Staff | 1975 |
| Julian Pei | Head of Investor Relations & Corporate Finance | — |
| Dr. Katy Barglow Ph.D. | Chief Technical Officer | — |
| Dr. Scott P. Bizily J.D., Ph.D. | Chief Legal Officer & Corporate Secretary | 1972 |
| Dr. An Song Ph.D. | Chief Translational Medicine Advisor | — |
| Dr. Noriyuki Kasahara M.D., Ph.D. | Chief Scientific Advisor | 1963 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 24, 2026
Technical indicators
- RSI 14
- 39.04
- MACD 12/26/9
- -0.45
- EMA 9 of MACD
- -0.38
- MACD histogram
- -0.08
- SMA 50
- $14.01
- Price below SMA 50
- EMA 50
- $13.16
- Price below EMA 50
- SMA 200
- $10.75
- Price above SMA 200
- EMA 200
- $11.41
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $20.00
- Average
- $30.20
- High
- $37.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -27.0 | -4.6 | -3.2 | |||||||||
| 2022 | -30.2 | -13.2 | +11.0 | -22.5 | -39.7 | -8.2 | +35.1 | -12.8 | +0.0 | +10.9 | +170.4 | -3.7 |
| 2023 | +2.0 | -10.4 | -6.4 | +4.0 | -2.1 | -0.1 | +2.5 | -12.0 | -23.1 | -9.1 | +19.1 | +52.6 |
| 2024 | -18.8 | +50.1 | +8.5 | -20.3 | -5.6 | -15.1 | -16.9 | -12.7 | -26.7 | -23.1 | -3.2 | -26.6 |
| 2025 | -3.9 | -23.6 | -22.0 | +12.7 | +5.2 | -1.1 | +8.4 | -4.0 | +41.5 | +31.7 | +3.9 | -28.6 |
| 2026 | +21.0 | +5.6 | -0.2 | -10.1 | +9.0 | +37.0 | -19.8 | +39.8 | -0.3 | -14.4 |



